Aelis Farma SA (EPA:AELIS)

Market Cap	17.32M +1.7%
Revenue (ttm)	2.33M -78.4%
Net Income	-8.20M
EPS	-0.60
Shares Out	13.59M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	73,552
Average Volume	26,275
Open	1.180
Previous Close	1.230
Day's Range	1.178 - 1.278
52-Week Range	0.672 - 2.300
Beta	0.60
RSI	46.84
Earnings Date	Mar 30, 2026

About Aelis Farma

Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France. The company is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which is in phase II clinical trials to treat cognitive deficits observed in down syndrome, as well as other cognitive imp...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 24
• Stock Exchange: Euronext Paris
• Ticker Symbol: AELIS

Financial Performance

In 2024, Aelis Farma's revenue was 5.56 million, a decrease of -54.99% compared to the previous year's 12.36 million. Losses were -7.46 million, 46.8% more than in 2023.